{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:26:51Z","timestamp":1776389211268,"version":"3.51.2"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2022,2,11]]},"abstract":"<jats:p>Background. Bone marrow infiltration of lymphoma cells is a candidate risk factor for infusion-related reactions (IRRs) in patients with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). However, despite with the lack of sufficient data, the effect of bone marrow infiltration of B-NHL cells on the incidence rate of grade 2 or higher IRRs with the administration of rituximab has been retrospectively studied in this paper. Methods. Patients with CD20-positive B-NHL who received the rituximab induction therapy for the first time were enrolled in this study. To evaluate the bone marrow infiltration of B-NHL cells, May\u2013Giemsa stain of bone marrow films and flow cytometry examination of bone marrow aspiration samples were performed. IRR grade was determined using the IRR criteria in the Common Terminology Criteria for Adverse Events version 4.0. Results. A total of 127 patients were eligible for this study. Grade 2 or higher IRRs were observed in 43 (34%) patients. In univariate analysis, use of glucocorticoid before rituximab infusion was a strong risk-avoiding factor for grade 2 or higher IRRs. Advanced stage of disease (Ann Arbor: stages III and IV) or bone marrow infiltration of B-NHL cells revealed the risk factors, regardless of glucocorticoid premedication. Using multivariate analysis, bone marrow infiltration was found to be an independent risk factor for patients without prior glucocorticoid use. Conclusion. Bone marrow infiltration of B-NHL cells is a risk factor for grade 2 or higher IRRs at the first rituximab induction therapy without glucocorticoid premedication.<\/jats:p>","DOI":"10.1155\/2022\/3688727","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:35:06Z","timestamp":1644597306000},"page":"1-7","source":"Crossref","is-referenced-by-count":13,"title":["Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.1155","volume":"2022","author":[{"given":"Shinya","family":"Ohata","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Hyogo, Japan"},{"name":"Department of Oncology and Hematology, Kobe University Hospital, Kobe, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Faculty of Nursing and Medical Care, Keio University, Tokyo, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-5323","authenticated-orcid":true,"given":"Takeshi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2015.0043"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218883"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1313-5"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958010-00009"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.7.2217.419k02_2217_2224"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0329-5"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00005"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.3.791"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0429-3"},{"issue":"Suppl 12","key":"11","first-page":"53","article-title":"Optimizing the use of rituximab for treatment of B-cell non-Hodgkin\u2019s lymphoma: a benefit-risk update","volume":"27","author":"L. Kunkel","year":"2000","journal-title":"Seminars in Oncology"},{"key":"12","first-page":"674","article-title":"Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-hodgkin\u2019s lymphoma","volume":"70","author":"T. Tachi","year":"2015","journal-title":"Pharmazie"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.001"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.036"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1639-9"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.019"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1159\/000357711"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011795"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.09.131"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(06)70664-7"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70481-3"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3332-3"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03859-6"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.261"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1159\/000089461"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.31.4187"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.09.215"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0049-z"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.604"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2019.182"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/3688727.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/3688727.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/3688727.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:35:12Z","timestamp":1644597312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ah\/2022\/3688727\/"}},"subtitle":[],"editor":[{"given":"Estella M.","family":"Matutes","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":32,"alternative-id":["3688727","3688727"],"URL":"https:\/\/doi.org\/10.1155\/2022\/3688727","relation":{},"ISSN":["1687-9112","1687-9104"],"issn-type":[{"value":"1687-9112","type":"electronic"},{"value":"1687-9104","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}